Wikipedia

Diridavumab

Diridavumab (CR6261) (INN[1]) is a monoclonal antibody designed for the treatment of influenza A.[2]

Diridavumab
Monoclonal antibody
Type?
SourceHuman
Targethemagglutinin
Clinical data
Other namesCR6261
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6400H9934N1702O1996S48
Molar mass144196.67 g·mol−1

This drug was developed by Janssen Pharmaceutical Companies of Johnson & Johnson.

References

edit
  1. ^ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Diridavumab, American Medical Association.
 

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wiki.x.io/w/index.php?title=Diridavumab&oldid=1187849230"